Premenstrual Dysphoric Disorder (PMDD)

DSM-5 Diagnostic Criteria

The DSM-5 requires that a patient experience five or more symptoms in most menstrual cycles during the final week before menses onset, with those symptoms improving within a few days after menses begins, and becoming minimal or absent in the week following menstruation. This cyclicity — documented prospectively, not recalled retrospectively — is the cornerstone of the diagnosis.

At least one of the following core mood symptoms must be present: (1) marked affective lability such as sudden tearfulness, sadness, or increased sensitivity to rejection; (2) marked irritability, anger, or increased interpersonal conflicts; (3) marked depressed mood, feelings of hopelessness, or self-deprecating thoughts; or (4) marked anxiety, tension, or feelings of being keyed up or on edge.

Additional symptoms that contribute toward the five-symptom threshold include: decreased interest in usual activities such as work, hobbies, and socializing; difficulty concentrating; marked lethargy, easy fatigability, or lack of energy; marked change in appetite, overeating, or specific food cravings; hypersomnia or insomnia; a subjective sense of being overwhelmed or out of control; and physical symptoms such as breast tenderness or swelling, joint or muscle pain, bloating, or a sensation of weight gain.

The symptoms must cause clinically significant distress or interfere with work, school, social activities, or relationships, and must not be attributable to the physiological effects of a substance or another medical condition. The pattern must be confirmed by prospective daily ratings for at least two symptomatic cycles using a validated instrument such as the Daily Record of Severity of Problems (DRSP). Cycle-tracking apps can also be used for this daily documentation.

A critical differential is premenstrual exacerbation (PME) of an underlying condition — depression, anxiety disorder, migraine, or irritable bowel syndrome can all worsen in the luteal phase without representing true PMDD. In PME, symptoms are present throughout the cycle and amplify premenstrually; in PMDD, the follicular phase is genuinely symptom-free. Retrospective recall systematically underestimates symptom intensity and misses this distinction, which is why prospective charting is mandatory.

Back to Table of Contents

Pathophysiology

PMDD is fundamentally a disorder of central nervous system sensitivity to normal ovarian steroid cycling — not an abnormality in hormone levels themselves. This distinction is supported by three key lines of evidence. First, administering a GnRH (gonadotropin-releasing hormone) agonist to suppress ovarian cycling eliminates PMDD symptoms in the majority of patients. Second, when progesterone is added back to these women, it re-triggers PMDD symptoms — but not in women without PMDD. Third, adding back estrogen alone does not trigger symptoms, implicating progesterone and its metabolites rather than estrogen as the proximate trigger.

The central player is allopregnanolone (3α-hydroxy-5α-pregnan-20-one; also called 3α-THP), a neurosteroid synthesized primarily from progesterone in the brain and adrenal glands. Allopregnanolone is a potent positive allosteric modulator of gamma-aminobutyric acid-A receptors, particularly the extrasynaptic δ-subunit-containing receptors that mediate tonic (continuous background) inhibition in neurons. Allopregnanolone concentrations rise significantly during the luteal phase. Under normal circumstances this rise produces anxiolytic, sedating, and calming effects — similar in mechanism to alcohol and benzodiazepines, though through different binding sites.

In women with PMDD, altered expression and sensitivity of gamma-aminobutyric acid-A receptor subunits and abnormalities in the serotonin system cause this ordinarily calming neurosteroid to produce a paradoxical excitatory effect — anxiety, irritability, and dysphoria rather than calm. This paradox is mechanistically similar to what is seen during alcohol withdrawal, where changes in gamma-aminobutyric acid-A receptor composition during chronic alcohol exposure cause anxiety when gamma-aminobutyric acid-A activity is restored. It explains why brexanolone (intravenous-administered allopregnanolone, approved for postpartum depression) works effectively — the dosing and delivery bypasses the sensitized receptors — while oral progesterone supplements reliably worsen PMDD symptoms.

The serotonin system is also implicated. Women with PMDD show reduced serotonin transporter (5-HTT) function during the luteal phase, lower platelet serotonin levels, and altered 5-HT1A receptor activity. This serotonergic dysregulation explains why selective serotonin reuptake inhibitors — which do not acutely elevate serotonin levels but modulate serotonin receptor sensitivity — produce therapeutic effects within days in PMDD, far faster than their weeks-long onset in major depression. The rapid response suggests selective serotonin reuptake inhibitors are acutely modulating neuroactive steroid synthesis or receptor sensitivity rather than correcting a classical monoamine deficit.

Genetic research has added another layer. The study by Dubey et al. (2017) found that cultured immune cell lines (lymphoblastoid cell lines) from PMDD patients — cells grown from blood, outside the brain — show different patterns of gene expression from the ESC/E(Z) epigenetic regulatory complex compared to healthy controls. This epigenetic sensitivity appears to affect how genes across multiple cell types respond to ovarian steroids, suggesting PMDD reflects a genome-wide sensitivity rather than a purely localized brain vulnerability.

Back to Table of Contents

Treatment — Selective Serotonin Reuptake Inhibitors (First-Line)

Selective serotonin reuptake inhibitors are the established first-line pharmacological treatment for PMDD, supported by extensive randomized controlled trial evidence and three U.S. Food and Drug Administration (FDA) approvals. Fluoxetine (20 mg/day) was the first U.S. Food and Drug Administration-approved treatment. Sertraline (50–150 mg/day) and paroxetine CR (12.5–25 mg/day) are also U.S. Food and Drug Administration-approved. A 2004 review of luteal-phase dosing (Freeman) lists sertraline, fluoxetine and extended-release paroxetine as FDA-approved for luteal-phase as well as continuous dosing, and reports that discontinuation symptoms with this intermittent regimen have not been reported.

The most striking feature of selective serotonin reuptake inhibitor (SSRI) treatment in PMDD is the speed of response. Unlike major depression where 4–6 weeks is typically required to detect clinical benefit, PMDD patients often report meaningful improvement within the first 1–2 days of selective serotonin reuptake inhibitor administration and within 1–2 menstrual cycles of starting treatment. This rapid onset — faster than any possible synaptic serotonin level change — strongly suggests that the therapeutic mechanism involves acute modulation of neuroactive steroid synthesis or gamma-aminobutyric acid-A receptor sensitivity rather than classic monoamine reuptake inhibition.

Two main dosing strategies are available with comparable efficacy:

• Continuous dosing — the selective serotonin reuptake inhibitor is taken every day of the cycle at standard doses. Preferred when follicular-phase symptoms are present, when the patient has difficulty tracking her cycle, or when cycle irregularity makes luteal-phase timing unreliable.
• Luteal-phase dosing — the selective serotonin reuptake inhibitor is started approximately on day 14 of the cycle (after confirmed ovulation, ideally confirmed with an ovulation predictor kit or cycle tracking) and discontinued with menses onset or 1–2 days after. This strategy is equally effective to continuous dosing in multiple studies and meta-analyses (Freeman et al. 2004). It reduces total medication exposure, side-effect burden, and cost. Standard doses: sertraline 50 mg/day or fluoxetine 20 mg/day during the luteal phase.

Overall selective serotonin reuptake inhibitor response rates in PMDD are approximately 65–75%, substantially higher than in major depression. Non-response to one selective serotonin reuptake inhibitor does not predict non-response to another — switching within the class is reasonable before moving to second-line treatments. Common side effects during the luteal phase include nausea (often transient), insomnia, sexual dysfunction, and headache. These are generally milder with intermittent luteal-phase dosing.

Back to Table of Contents

Treatment — Hormonal and Second-Line

GnRH agonists (leuprolide acetate, nafarelin, buserelin) produce a medical "chemical ovariectomy" by downregulating pituitary GnRH receptors, suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and eliminating ovarian cycling entirely. Because PMDD depends on luteal-phase hormonal cycling, GnRH agonists are 75–100% effective for PMDD symptoms. However, prolonged use produces menopausal side effects — hot flashes, vaginal dryness, insomnia, and critically, bone mineral density loss that becomes significant beyond 6 months of continuous use. Add-back therapy (low-dose estrogen plus a low-dose progestin) can extend GnRH agonist use while partially mitigating bone loss and vasomotor symptoms, though it reintroduces some hormonal fluctuation. GnRH agonists are most appropriate for severe treatment-resistant PMDD, or as a diagnostic and therapeutic bridge for women considering oophorectomy.

Oral contraceptives vary substantially in their effect on PMDD. The drospirenone-containing combined oral contraceptive drospirenone/ethinyl estradiol (3 mg drospirenone + 20 mcg ethinyl estradiol, extended 24/4 regimen) is U.S. Food and Drug Administration-approved for PMDD. Drospirenone is a progestin with anti-androgenic and antimineralocorticoid (anti-aldosterone) properties that distinguish it from older progestins. A placebo-controlled trial (Pearlstein et al. 2005) found significant reductions in PMDD symptom scores versus placebo. Continuous or extended cycling (minimizing hormone-free intervals) is described as preferable in PMDD because it limits withdrawal-related symptom recurrence. By contrast, levonorgestrel-containing pills and some other progestin formulations can worsen mood symptoms in susceptible women, and the research raises a concern about them for people with PMDD.

Spironolactone (50–100 mg/day during the luteal phase) is an aldosterone antagonist with anti-androgenic activity. It reduces bloating, breast tenderness, and water retention — the physical symptom cluster of PMDD — and provides modest mood benefit. It requires monitoring of serum potassium (risk of hyperkalemia, particularly with nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin-converting enzyme inhibitors (ACE inhibitors), or angiotensin receptor blockers (ARBs)), blood pressure, and renal function. It is most useful for patients whose predominant complaint is physical symptom burden rather than severe mood dysregulation.

Alprazolam (a short-acting benzodiazepine) in low doses during the luteal phase has been studied in treatment-resistant PMDD with predominant anxiety. Evidence is modest; dependency risk is significant. It is reserved for carefully selected refractory cases managed by specialists familiar with benzodiazepine prescribing.

Calcium carbonate at 1200 mg/day (elemental calcium) has consistent, if modest, randomized controlled trial (RCT) evidence for reducing both mood and physical symptoms of PMDD. A large randomized controlled trial in premenstrual syndrome (PMS) (Thys-Jacobs et al. 1998, 466 women) found that 1200 mg/day of calcium for three menstrual cycles lowered total symptom scores by 48% from baseline, compared with 30% on placebo; negative affect, water retention, food cravings, and pain were all significantly reduced by the third cycle. The mechanism may involve calcium's role in regulating calcitriol and serotonin synthesis, or correction of subclinical calcium deficiency common in menstruating women. It is inexpensive, and the trial authors described it as a simple and effective treatment in premenstrual syndrome.

Vitamin B6 (pyridoxine, 50–100 mg/day) has been studied as adjunctive therapy. Evidence is mixed; doses above 100 mg/day risk peripheral neuropathy with prolonged use. Magnesium supplementation has modest evidence for physical symptom reduction. Neither replaces first-line treatment but may reduce overall symptom burden when combined with selective serotonin reuptake inhibitor therapy.

Back to Table of Contents

Non-Pharmacological Treatments

Cognitive behavioral therapy (CBT) has randomized controlled trial evidence in PMDD. CBT targeting PMDD addresses catastrophizing around symptom recurrence, emotion regulation skills, interpersonal communication strategies for the luteal phase, and behavioral activation to counteract social withdrawal. A key cognitive behavioral therapy principle in PMDD is anticipatory coping — patients learn to recognize the luteal phase early, prepare coping strategies in advance, and reduce impulsive decisions (quitting jobs, ending relationships) that are temporally associated with peak symptoms but often regretted in the follicular phase. Cognitive behavioral therapy is particularly useful for patients who prefer not to use medications, those with mild-moderate symptom severity, or as an adjunct to pharmacotherapy for residual psychosocial impairment.

Aerobic exercise demonstrates consistent benefit across observational studies and several controlled trials. Regular aerobic exercise at least 4 times per week appears to reduce overall PMDD severity, including both mood and physical symptom components. Proposed mechanisms include endorphin release, serotonin system modulation, and reduction of the inflammatory signaling that correlates with luteal-phase symptom peaks. Exercise timing across the cycle does not appear to substantially alter the benefit — consistent routine matters more than strategic cycling-phase timing.

Dietary modifications are commonly recommended on the basis of mechanistic plausibility and patient-reported benefit, though randomized controlled trial evidence is limited. Reduced caffeine intake (caffeine is anxiogenic and worsens irritability and insomnia, symptoms that are already amplified in the PMDD luteal phase) and reduced alcohol consumption (alcohol disrupts sleep architecture, worsens dysphoria via rebound effects, and interacts with allopregnanolone-GABA pathways) are prudent recommendations for symptomatic luteal-phase management. Reducing refined sugar and sodium may help with physical symptom burden — bloating, fluid retention, and energy crashes — though the evidence base is largely observational.

Sleep hygiene optimization is important because sleep deprivation dramatically worsens mood dysregulation, irritability, and the capacity to manage interpersonal conflict — all PMDD symptoms. Consistent sleep and wake times, minimizing blue-light exposure before bed, and avoiding caffeine after noon are standard recommendations that carry particular value in the symptomatic luteal phase.

Bright light therapy has preliminary evidence for benefit in PMDD, particularly for patients who notice seasonal worsening of their luteal-phase symptoms — a recognized overlap between PMDD and seasonal affective disorder (SAD). Standard bright-light devices (10,000 lux, 20–30 minutes in the morning) carry an excellent safety profile. Acupuncture has been investigated in several small randomized trials with mixed but generally positive results; evidence is insufficient to recommend it as a primary treatment but it can be offered as a complementary option for patients who prefer integrative approaches.

Back to Table of Contents

Diagnosis and Prospective Charting

The diagnosis of PMDD cannot be established on the basis of history alone. Prospective daily symptom charting across at least two consecutive symptomatic cycles is required. This requirement exists because retrospective recall of premenstrual symptoms is systematically inaccurate — women tend to recall symptoms as worse than daily ratings confirm, and recall bias can produce apparent PMDD in women who actually have premenstrual exacerbation of another condition. Multiple studies have found that 30–50% of women who report PMDD by history do not meet criteria on prospective charting.

The Daily Record of Severity of Problems (DRSP) is the most widely used and validated instrument for prospective PMDD charting. It rates 21 items daily on a scale of 1–6, spanning mood symptoms, behavioral changes, and physical complaints. The pattern that confirms PMDD is a clear premenstrual rise beginning after ovulation, peak in the luteal phase, and fall to near-baseline within 2–4 days of menstrual onset, followed by a symptom-free follicular phase.

Digital tracking applications have made prospective charting far more feasible in clinical practice. Cycle-tracking apps allow daily symptom logging with graphical displays that can be exported or reviewed at follow-up appointments. The purpose of daily charting matters to patients — it is not meant to dismiss the patient's experience but to confirm the pattern that determines the most effective treatment strategy. Many patients find that charting itself is therapeutic because it objectifies what felt like unpredictable chaos.

The laboratory workup for suspected PMDD is relatively brief, aimed at excluding conditions that can masquerade as or coexist with PMDD. Thyroid-stimulating hormone (TSH) is checked to exclude hypothyroidism, which causes fatigue, depression, and cognitive changes that are not cycle-dependent but may appear to worsen premenstrually in susceptible women. A complete blood count (CBC) can identify iron-deficiency anemia contributing to fatigue and cognitive difficulties. Follicle-stimulating hormone (FSH) is appropriate in perimenopausal women to assess ovarian reserve, as the hormonal transitions of perimenopause frequently worsen or unmask PMDD-like symptoms.

The critical differential diagnosis to exclude at the diagnostic stage is premenstrual exacerbation (PME) of a primary psychiatric disorder. Depression, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder all commonly worsen premenstrually without fulfilling PMDD criteria — because symptoms persist (at lower intensity) throughout the follicular phase. The clinical implication is important: in PME, the primary condition requires treatment, not PMDD-specific interventions. Prospective charting reliably distinguishes the two by demonstrating whether a symptom-free follicular window truly exists.

Back to Table of Contents

Disability and Quality of Life

The functional impact of PMDD is frequently underestimated by clinicians, employers, and family members — and often by patients themselves, who may have internalized the cultural message that premenstrual symptoms are normal and should be endured. In reality, severe PMDD causes clinically significant functional impairment for an average of 7–14 days per month — one-quarter to one-half of a woman's adult life spent in a state of significant psychological and physical distress.

Occupational impact is substantial. Women with PMDD report significantly higher rates of work absenteeism and presenteeism (reduced productivity while at work) during the luteal phase compared to controls. A large European study found that PMDD was associated with work impairment comparable to that seen in major depression — a condition universally recognized as disabling. Academic performance shows analogous impairment in students, with test anxiety, concentration difficulties, and social withdrawal clustering in luteal-phase weeks.

Relationship impact is also severe. Marital and partnership conflict peaks during the luteal phase in PMDD patients; partners report unpredictable anger, emotional distance, and rejection sensitivity that strains relationships over time. Critically, partners who understand the biological basis of PMDD — that the person they love is experiencing a predictable, biologically driven state — demonstrate markedly better coping and relationship satisfaction than those who attribute symptoms to personality or willfulness. Partner psychoeducation is an underutilized therapeutic tool.

Co-occurring conditions are common in PMDD and compound functional impairment. Major depression and anxiety disorders are the most prevalent comorbidities. Post-traumatic stress disorder is significantly overrepresented in PMDD patients, though the causal direction is uncertain — the hyperarousal and emotional reactivity of post-traumatic stress disorder may share neurobiological pathways with PMDD sensitivity. Endometriosis occurs at elevated rates in PMDD patients, creating a compound burden of physical pain and mood dysregulation that is often underdiagnosed and undertreated. Chronic pain conditions, migraine (with documented perimenstrual migraine clustering), and irritable bowel syndrome (IBS, which worsens premenstrually in many women) also co-occur with PMDD.

A critical message for patients is that PMDD is not a personality disorder, not a character flaw, and not a choice. Biological conditions that impair functioning deserve treatment. Validation — from clinicians, partners, employers, and the patient herself — is itself therapeutic. Many women with PMDD have spent years being told that their suffering is "just PMS," "all in their head," or a sign of emotional immaturity. Providing an accurate biological framework for PMDD frequently produces substantial relief independent of any pharmacological intervention.

Back to Table of Contents

Suicidality and Crisis Planning

A significant and underrecognized subgroup of women with PMDD experiences passive suicidal ideation, active suicidal ideation, or self-harm ideation confined to the luteal phase, resolving spontaneously with menstrual onset. A study by Pilver et al. (2013) in Social Psychiatry and Psychiatric Epidemiology, using survey data from 3,965 American women, found that women with PMDD were about twice as likely as women with no premenstrual symptoms to report suicidal ideation, plans, and attempts, after adjusting for other psychiatric conditions. Population-based data suggest that 15–30% of women with PMDD report some degree of luteal-phase suicidal ideation. Hospitalizations for self-harm and suicidal crises cluster during the luteal phase in this population.

The paradox of PMDD-associated suicidality is that it is simultaneously serious and, in most cases, highly predictable and time-limited. Unlike suicidal ideation in major depression — which may be persistent, escalating, and poorly bounded — PMDD suicidal ideation is typically self-terminating within days of menstrual onset. The patient herself often knows this from prior cycles. This cyclicity can be a source of resilience when properly communicated and incorporated into a safety plan: "I know this is the PMDD, I know it will pass in approximately X days, and I have a plan to keep myself safe until it does."

Clinical management of suicidality in PMDD:

• Assess and document suicidal ideation at every visit, including cycle phase at time of assessment. Ideation rated during the follicular phase substantially underestimates luteal-phase risk.
• Psychoeducation about cyclicity — explain that the ideation is a symptom of the disorder, not a reflection of the patient's true desires or the reality of her situation. Many patients find this framing profoundly relieving.
• Written safety plan for the luteal phase — developed in advance, during the follicular phase when the patient is clearest, covering warning signs, coping strategies, crisis contacts (988 Suicide & Crisis Lifeline: call or text 988), and means restriction.
• Means restriction — in severe cases, reduce access to lethal means during the luteal phase (e.g., firearm storage with a trusted person, medication lockboxes).
• Pharmacological urgency — in patients with luteal-phase suicidality, selective serotonin reuptake inhibitor initiation is urgent, not optional. The rapid selective serotonin reuptake inhibitor response in PMDD — often within days — means treatment can reduce suicidal ideation within the same or following cycle.
• GnRH agonist for severe, refractory cases — eliminating ovarian cycling eliminates the luteal-phase trigger for suicidal ideation; this may be medically appropriate as a bridge to more definitive management in women with severe PMDD and recurrent suicidal crises.

PMDD-related suicidality carries the same seriousness as any other suicidal ideation, and explaining the biology of cyclicity clearly matters — both to reduce stigma and to provide the patient with an evidence-based framework for understanding her own experience. Statements like "that's just your hormones talking" are dismissive and clinically harmful; "your brain is responding to a hormonal signal in a way we can treat" is accurate, validating, and actionable.

Back to Table of Contents

Key Research Papers

1. Dubey N et al. (2017). The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder. Molecular Psychiatry. — PubMed PMID: 28044059
2. Hantsoo L, Epperson CN. (2015). Premenstrual Dysphoric Disorder: Epidemiology and Treatment. Current Psychiatry Reports. — PubMed PMID: 26377947
3. Yonkers KA et al. (2008). Premenstrual syndrome. Lancet. — Search PubMed
4. Pearlstein TB et al. (2005). Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. — PubMed PMID: 16307962
5. Endicott J et al. (1999). Is premenstrual dysphoric disorder a distinct clinical entity? Journal of Women's Health & Gender-Based Medicine. — PubMed PMID: 10839653
6. Pilver CE et al. (2013). Premenstrual dysphoric disorder as a correlate of suicidal ideation, plans, and attempts among a nationally representative sample. Social Psychiatry and Psychiatric Epidemiology. — PubMed PMID: 22752111
7. Rubinow DR, Schmidt PJ. (2006). Gonadal steroid regulation of mood: the lessons of premenstrual syndrome. Frontiers in Neuroendocrinology. — PubMed PMID: 16650465
8. Freeman EW. (2004). Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs. — PubMed PMID: 15139800
9. Rapkin AJ. (2003). A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology. — PubMed PMID: 12892989
10. Halbreich U et al. (2003). The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder. Psychoneuroendocrinology. — PubMed PMID: 12892987
11. Backstrom T et al. (2003). The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs. — Search PubMed
12. Steiner M et al. (2006). Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. Journal of Women's Health. — PubMed PMID: 16417420

Back to Table of Contents

Connections

• Psychiatry
• Serotonin, Mood & Selective Serotonin Reuptake Inhibitors — interactive animation
• PMS and PMDD
• Postpartum Depression
• Depression
• Anxiety
• Seasonal Affective Disorder
• Insomnia
• Eating Disorders
• Borderline Personality Disorder
• Magnesium
• Calcium
• Vitamin B6
• Endometriosis
• Herbs covered on this site that discuss this condition: Saffron · Motherwort · Red Raspberry Leaf

Back to Table of Contents

Featured Videos

×